{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T07:23:22Z","timestamp":1778916202411,"version":"3.51.4"},"reference-count":60,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2021,11,28]],"date-time":"2021-11-28T00:00:00Z","timestamp":1638057600000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"M.A.C. AIDS Fund"},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["CO-NL-276-4222"],"award-info":[{"award-number":["CO-NL-276-4222"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["CO-US-276-1712"],"award-info":[{"award-number":["CO-US-276-1712"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["PA-HIV-PREP-16-0024"],"award-info":[{"award-number":["PA-HIV-PREP-16-0024"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bristol-Myers Squibb International","award":["AI424-541"],"award-info":[{"award-number":["AI424-541"]}]},{"name":"Amsterdam Dinner Foundation"},{"name":"Aidsfonds","award":["2013169"],"award-info":[{"award-number":["2013169"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,10,14]]},"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Initiation of combination antiretroviral therapy (cART) during acute or early HIV-infection (AEHI) limits the size of the viral reservoir and preserves immune function. This renders individuals who started cART during AEHI promising participants in HIV-cure trials. Therefore, we established a multicentre prospective cohort study in the Netherlands that enrols people with AEHI. In anticipation of future cure trials, we will longitudinally investigate the properties of the viral reservoir size and HIV-specific immune responses among cohort participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Participants immediately initiate intensified cART: dolutegravir, emtricitabine\/tenofovir and darunavir\/ritonavir (DRV\/r). After 4\u2009weeks, once baseline resistance data are available, DRV\/r is discontinued. Three study groups are assembled based on the preparedness of individuals to participate in the extensiveness of sampling. Participants accepting immediate treatment and follow-up but declining additional sampling are included in study group 1 (\u2018standard\u2019) and routine diagnostic procedures are performed. Participants willing to undergo blood, leukapheresis and semen sampling are included in study group 2 (\u2018less invasive\u2019). In study group 3 (\u2018extended\u2019), additional tissue (gut-associated lymphoid tissue, peripheral lymph node) and cerebrospinal fluid sampling are performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings to date<\/jats:title>\n                    <jats:p>\n                      Between 2015 and 2020, 140 individuals with AEHI have been enrolled at nine study sites. At enrolment, median age was 36 (IQR 28\u201347) years, and 134 (95.7%) participants were men. Distribution of Fiebig stages was as follows: Fiebig I, 3 (2.1%); II, 20 (14.3%); III, 7 (5.0%); IV, 49 (35.0%); V, 39 (27.9%); VI, 22 (15.7%). Median plasma HIV RNA was 5.9 (IQR 4.7\u20136.7) log10 copies\/mL and CD4 count 510 (IQR 370\u2013700) cells\/mm\n                      <jats:sup>3<\/jats:sup>\n                      . Median time from cART initiation to viral suppression was 8.0 (IQR 4.0\u201316.0) weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Future plans<\/jats:title>\n                    <jats:p>The Netherlands Cohort Study on Acute HIV infection remains open for participant enrolment and for additional sites to join the network. This cohort provides a unique nationwide platform for conducting future in-depth virological, immunological, host genetic and interventional studies investigating HIV-cure strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-048582","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T11:10:35Z","timestamp":1638184235000},"page":"e048582","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Cohort profile: the Netherlands Cohort Study on Acute HIV infection (NOVA), a prospective cohort study of people with acute or early HIV infection who immediately initiate HIV treatment"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct00296660","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02859558","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02656511","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03449706","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00537966","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2561-7659","authenticated-orcid":false,"given":"Maartje","family":"Dijkstra","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, Netherlands"},{"name":"Department of Internal Medicine, Division of Infectious Diseases, Amsterdam Institute for Infection and Immunity (AII), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1452-7271","authenticated-orcid":false,"given":"Henrieke","family":"Prins","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Erasmus University Medical Center, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan M","family":"Prins","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Amsterdam Institute for Infection and Immunity (AII), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Reiss","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Amsterdam Institute for Infection and Immunity (AII), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands"},{"name":"HIV Monitoring Foundation, Amsterdam, Noord-Holland, Netherlands"},{"name":"Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Boucher","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annelies","family":"Verbon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Erasmus University Medical Center, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casper","family":"Rokx","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Erasmus University Medical Center, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Godelieve","family":"de Bree","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Amsterdam University Medical Centre, Amsterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"2025121509422662000_11.11.e048582.1","unstructured":"Joint United nations programme on HIV\/AIDS (UNAIDS) . Ending the AIDS epidemic fact sheet - World AIDS Day, 2020. Available: https:\/\/www.unaids.org\/en\/resources\/fact-sheet"},{"key":"2025121509422662000_11.11.e048582.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809866"},{"key":"2025121509422662000_11.11.e048582.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814556"},{"key":"2025121509422662000_11.11.e048582.4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10461-015-1164-1","article-title":"The association of HIV-related stigma to HIV medication adherence: a systematic review and synthesis of the literature","volume":"20","author":"Sweeney","year":"2016","journal-title":"AIDS Behav"},{"key":"2025121509422662000_11.11.e048582.5","doi-asserted-by":"crossref","first-page":"e835","DOI":"10.1016\/S2352-3018(20)30197-1","article-title":"Burden of living with HIV among men who have sex with men: a mixed-methods study","volume":"7","author":"van Bilsen","year":"2020","journal-title":"Lancet HIV"},{"key":"2025121509422662000_11.11.e048582.6","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1097\/QAD.0000000000001511","article-title":"Impact of comorbidity and ageing on health-related quality of life in HIV-positive and HIV-negative individuals","volume":"31","author":"Langebeek","year":"2017","journal-title":"AIDS"},{"key":"2025121509422662000_11.11.e048582.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1841-8"},{"key":"2025121509422662000_11.11.e048582.8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003211"},{"key":"2025121509422662000_11.11.e048582.9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jve.2020.100004","article-title":"A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection","volume":"6","author":"Kroon","year":"2020","journal-title":"J Virus Erad"},{"key":"2025121509422662000_11.11.e048582.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506816"},{"key":"2025121509422662000_11.11.e048582.11","doi-asserted-by":"publisher","DOI":"10.1038\/nature13594"},{"key":"2025121509422662000_11.11.e048582.12","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis326"},{"key":"2025121509422662000_11.11.e048582.13","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4156"},{"key":"2025121509422662000_11.11.e048582.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.09.020"},{"key":"2025121509422662000_11.11.e048582.15","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e328361faf4"},{"key":"2025121509422662000_11.11.e048582.16","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1972"},{"key":"2025121509422662000_11.11.e048582.17","doi-asserted-by":"publisher","DOI":"10.1038\/387183a0"},{"key":"2025121509422662000_11.11.e048582.18","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5341.1295"},{"key":"2025121509422662000_11.11.e048582.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302976"},{"key":"2025121509422662000_11.11.e048582.20","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833b61ba"},{"key":"2025121509422662000_11.11.e048582.21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ebiom.2016.07.024","article-title":"Hiv DNA set point is rapidly established in acute HIV infection and dramatically reduced by early art","volume":"11","author":"Ananworanich","year":"2016","journal-title":"EBioMedicine"},{"key":"2025121509422662000_11.11.e048582.22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033948"},{"key":"2025121509422662000_11.11.e048582.23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/QAD.0000000000000147","article-title":"What is the significance of posttreatment control of HIV infection vis-\u00e0-vis functional cure?","volume":"28","author":"Vanham","year":"2014","journal-title":"AIDS"},{"key":"2025121509422662000_11.11.e048582.24","doi-asserted-by":"publisher","DOI":"10.1086\/518250"},{"key":"2025121509422662000_11.11.e048582.25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1120248109"},{"key":"2025121509422662000_11.11.e048582.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0026-6"},{"key":"2025121509422662000_11.11.e048582.27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag1809","article-title":"Delayed differentiation of potent effector CD8+ T cells reducing viremia and reservoir seeding in acute HIV infection","volume":"9","author":"Takata","year":"2017","journal-title":"Sci Transl Med"},{"key":"2025121509422662000_11.11.e048582.28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau0528","article-title":"Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection","volume":"11","author":"Ndhlovu","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025121509422662000_11.11.e048582.29","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200309050-00005"},{"key":"2025121509422662000_11.11.e048582.30","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2508-4"},{"key":"2025121509422662000_11.11.e048582.31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1089\/aid.2017.0276","article-title":"No time to delay! Fiebig stages and referral in acute HIV infection: seattle primary infection program experience","volume":"34","author":"Stekler","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025121509422662000_11.11.e048582.32","unstructured":"van Sighem AI , FWNM W , Boyd A , et al . Human Immonudeficiency virus (HIV) infection in the Netherlands. 2020. Amsterdam: Stichting HIV Monitoring, 2019."},{"key":"2025121509422662000_11.11.e048582.33","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02425-17","article-title":"Mechanism of darunavir (DRV)'s high genetic barrier to HIV-1 resistance: a key V32I substitution in protease rarely occurs, but once it occurs, it predisposes HIV-1 to develop DRV resistance","volume":"9","author":"Aoki","year":"2018","journal-title":"mBio"},{"key":"2025121509422662000_11.11.e048582.34","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010371113"},{"key":"2025121509422662000_11.11.e048582.35","unstructured":"Hiv drug interactions, University of Liverpool. Available: https:\/\/www.hiv-druginteractions.org\/interactions\/97705; [Accessed 29 Oct 2020]."},{"key":"2025121509422662000_11.11.e048582.36","unstructured":"Prins HA , Zino L , Svensson EM . Pharmacokinetics of dolutegravir combined with ritonavir boosted darunavir in treatment-na\u00efve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA). Submitted 2021."},{"key":"2025121509422662000_11.11.e048582.37","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022516"},{"key":"2025121509422662000_11.11.e048582.38","article-title":"P4.105 Highly successful engagement in an acute hiv-infection (AHI) awareness campaign and intervention in amsterdam & its yield of ahi diagnoses at the city\u2019s sti clinic","volume":"93","author":"Davidovich","year":"2017","journal-title":"Sex Transm Infect"},{"key":"2025121509422662000_11.11.e048582.39","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2016-103427"},{"key":"2025121509422662000_11.11.e048582.40","unstructured":"Dijkstra M , Rennie S HLP . Perception and willingness to participate in HIV cure clinical trials among people who initiated treatment during acute HIV infection in Amsterdam. 23rd international AIDS conference, San Francisco: PEB0271, 2020."},{"key":"2025121509422662000_11.11.e048582.41","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001671"},{"key":"2025121509422662000_11.11.e048582.42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001196"},{"key":"2025121509422662000_11.11.e048582.43","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001148"},{"key":"2025121509422662000_11.11.e048582.44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3851\/IMP3080","article-title":"Outcomes of acutely HIV-1-infected individuals following rapid antiretroviral therapy initiation","volume":"22","author":"Girometti","year":"2017","journal-title":"Antivir Ther"},{"key":"2025121509422662000_11.11.e048582.45","doi-asserted-by":"publisher","DOI":"10.1038\/srep32947"},{"key":"2025121509422662000_11.11.e048582.46","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2007.026963"},{"key":"2025121509422662000_11.11.e048582.47","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001134"},{"key":"2025121509422662000_11.11.e048582.48","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1093\/cid\/ciaa505","article-title":"Decreased time to viral suppression after implementation of targeted testing and immediate initiation of treatment of acute human immunodeficiency virus infection among men who have sex with men in Amsterdam","volume":"72","author":"Dijkstra","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025121509422662000_11.11.e048582.49","article-title":"Significant impact of COVID-19 on HIV care in hospitals affecting the first Pillar of the HIV care continuum","author":"Hensley","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025121509422662000_11.11.e048582.50","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.18.1.20052"},{"key":"2025121509422662000_11.11.e048582.51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004078"},{"key":"2025121509422662000_11.11.e048582.52","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9495"},{"key":"2025121509422662000_11.11.e048582.53","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3018(18)30039-0","article-title":"Barriers and strategies to achieve a cure for HIV","volume":"5","author":"Pitman","year":"2018","journal-title":"Lancet HIV"},{"key":"2025121509422662000_11.11.e048582.54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jve.2021.100045","article-title":"Launching a multidisciplinary European collaboration towards a cure for HIV: the EU2Cure Consortium","volume":"7","author":"Rokx","year":"2021","journal-title":"J Virus Erad"},{"key":"2025121509422662000_11.11.e048582.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1609157"},{"key":"2025121509422662000_11.11.e048582.56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005339"},{"key":"2025121509422662000_11.11.e048582.57","doi-asserted-by":"publisher","DOI":"10.1007\/s00251-017-1000-z"},{"key":"2025121509422662000_11.11.e048582.58","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01832-18","article-title":"HIV subtype and Nef-mediated immune evasion function correlate with viral reservoir size in Early-Treated individuals","volume":"93","author":"Omondi","year":"2019","journal-title":"J Virol"},{"key":"2025121509422662000_11.11.e048582.59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2001855"},{"key":"2025121509422662000_11.11.e048582.60","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad1863"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-048582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:42:44Z","timestamp":1765820564000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-048582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":60,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,29]]},"published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1136\/bmjopen-2020-048582"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-048582","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}